Evolent Health Amends Credit Agreement for Flexibility

Evolent Health ( (EVH) ) has provided an update.

On June 19, 2025, Evolent Health, Inc. announced an amendment to its Credit Agreement to provide additional financial flexibility and secured a Commitment Letter with Ares Management Credit funds for non-dilutive debt capital to retire its 2025 Convertible Notes. The company reaffirmed its Adjusted EBITDA guidance for 2025, citing lower-than-expected oncology costs and an accelerated forecast for new revenue bookings in 2026, which will be supported by the additional capital.

The most recent analyst rating on (EVH) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.

Spark’s Take on EVH Stock

According to Spark, TipRanks’ AI Analyst, EVH is a Neutral.

Evolent Health’s stock score is primarily influenced by its financial performance challenges and technical analysis indicators, both suggesting caution. Despite promising guidance and expansion from the earnings call, the negative valuation metrics and bearish technical signals weigh heavily on the overall score.

To see Spark’s full report on EVH stock, click here.

More about Evolent Health

Evolent Health, Inc. is a company focused on achieving better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable. It serves a national base of leading payers and providers and is recognized as a top place to work in healthcare nationally.

Average Trading Volume: 2,184,524

Technical Sentiment Signal: Sell

Current Market Cap: $1.02B

For detailed information about EVH stock, go to TipRanks’ Stock Analysis page.